AlphaStocks
6.1
Consider Buy

JOHNSON & JOHNSON (JNJ)

Health Care / Pharmaceuticals

S&P 500

$224.14

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

#235out of 1126 in Health Care

Is JOHNSON & JOHNSON a Good Investment in 2026?

JOHNSON & JOHNSON (JNJ) scores 6.1 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Buffett model rates JOHNSON & JOHNSON as Attractive. However, the Graham model rates it Caution — Significantly above fair value. JOHNSON & JOHNSON currently trades below its estimated fair value of $311, suggesting potential upside. JOHNSON & JOHNSON ranks #235 out of 1126 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E20.3ROE33.3Market Cap548BDiv Yield2.2

Estimated Fair Value

$311.4528% below

Fair value above market price. EPS grew 91% year-over-year. ROE of 33% signals strong profitability. P/E of 20x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

High PEG — growth premium · Slow Grower

Greenblatt

Neutral

Top 10% (rank 8%)

Frequently Asked Questions

Is JOHNSON & JOHNSON (JNJ) a good investment?
Based on AlphaStocks' composite analysis, JOHNSON & JOHNSON (JNJ) scores 6.1 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Fair value above market price. EPS grew 91% year-over-year. ROE of 33% signals strong profitability. P/E of 20x is moderate for this quality level.
What is JOHNSON & JOHNSON's Piotroski F-Score?
JOHNSON & JOHNSON's Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is JNJ overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $311, JNJ appears undervalued. The stock currently trades 28% below its estimated fair value. Fair value above market price. EPS grew 91% year-over-year. ROE of 33% signals strong profitability. P/E of 20x is moderate for this quality level.
How does JNJ compare to other Health Care stocks?
JOHNSON & JOHNSON ranks #235 out of 1126 stocks in the Health Care sector, placing it in the top 21% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about JNJ?
AlphaStocks evaluates JNJ using five proven investment models. Piotroski: Neutral; Buffett: Attractive; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 6.1/10.

Similar Stocks

PARRFTIAZN

Compare JNJ with

JNJ vs PARRJNJ vs FTIJNJ vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer